We are 4-Methylpiperidine CAS:626-58-4 manufacturer and supplier in China, Pls send inquiry of to firstname.lastname@example.org of visit www.nbinno.com our official website should you have any interests
Chemical Name: 4-Methylpiperidine
Molecular Weight: 99.17410
Physical and Chemical Properties:
Density: 0.84 g / mL at 25 ° C (lit.)
Boiling point: 124 ° C763 mm Hg (lit.)
Melting point: 4-5° C
Flash point: 45 ° F
Refractive index: n20 / D 1.446 (lit.)
Appearance: colorless to yellow liquid
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Keep away from heat, sparks, and flame. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Corrosives area.
Application: 4-Methylpiperidine is used as a catalyst in the synthesis of stilbene derivatives as anti-malarial agents. It also serves as an anti-corrosive compound for iron.
Related News: Over the years, large international pharmaceutical companies have gradually focused on the research and development and sales of patented drugs, and have gradually outsourced traditional products. Among them, most of the contractors are pharmaceutical companies in emerging countries.oct-2-enal Over the years, large international pharmaceutical companies have gradually focused on the research and development and sales of patented drugs, and have gradually outsourced traditional products. Among them, most of the contractors are pharmaceutical companies in emerging countries.3-bromo-3'-chloro-1,1'-biphenyl When a new strain emerges that has not yet been identified, as is the case with the current outbreak in China, it temporarily becomes known as a novel coronavirus (nCoV).2-Chloro-1,3-dimethylimidazolidinium hexafluorophosphate The Company’s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line.The drug, Imfinzi, when added to chemotherapy and the drugmaker’s other cancer drug tremelimumab, significantly improved the survival of patients without the disease progressing, when compared to chemotherapy alone, the company said.